A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Children's Oncology Group
The overall goal of Part I of this study is to collect information about your leukemia and your response to the first phase of treatment, called Induction. Part I of the study is necessary to determine if you will be eligible for Part II, and to help decide the best treatment after Induction. The treatment involves cancer fighting medicines called chemotherapy. The treatment on this part of the study takes about one month.
This study is currently enrolling.